38 results about "Oncology drugs" patented technology

The present invention relates to methods of passive infrared imaging and dynamic infrared imaging of a tumor or lesion (“DIR”) where multiple images are taken before, during and after heating or cooling the tumor or lesion. Patterns of intensity of infrared emission in the infrared image(s) are related to the level of vascularity or metabolic activity of the tumor or lesion, and are used to identify size and shape of the tumor or lesion. The patterns can also be used to determine whether Kaposi's sarcoma lesions, skin cancer lesions and melanomas are active or inactive. Changes in the patterns of infrared emission determined by comparing images taken before, during and after the onset of drug or radiation therapy, are used to assess efficacy of the therapy. The methods can also be used to study tissue affected by angiogenic diseases.

The present invention provides a method of inhibiting the growth of or promoting differentiation and destruction of cancer stem cells (CSCs) comprising contacting the cancer stem cells with a compound having the structure:

or a pharmaceutically acceptable salt thereof.

The present invention belongs to the technical field of medicine and biology, and relates to an antitumor drug synergism drug, particularly to a tumor treatment synergism drug composition comprising an autophagy inhibitor and adriamycin. The combination drug comprises one or a plurality of autophagy inhibitors and adriamycin, and is provided for treating tumors by adopting a combination administration or sequential use mode, wherein tumor cell autophagy induced by adriamycin can be inhibited to counteract antagonism effects of tumors on treatments of adriamycin due to autophagy so as to significantly enhance tumor treatment effects of adriamycin. The synergism drug composition is suitable for treatment of lymphoma, lung cancers, brain tumors, breast cancers and myeloma.

The invention discloses application of an iridium complex in preparing mitochondria targeted anti-tumor drugs. The structural formula of the iridium complex is [Ir(ppy)2(HPIP)]C1, wherein ligand represented by ppy is 2-phenylpyridine, ligand represented by HPIP is 3-(1H-imidazole[4,5-f][1,10]phenanthroline-2-yl)phenol. The iridium complex has the high inhibiting effect on human tumor cells HeLa, HepG2, A-549 and a cisplatin resistant strain CP/R-A549, mitochondria in tumor cells can be stored up, tumor cell apoptosiss can be induced, and the iridium complex can serve as the new anti-tumor drugtaking tumor cell mitochondria as target sites.

The invention discloses a use of a bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors. Anti-cancer experiments of human tongue squamous cancer cells are carried out in vitro through a bufadienolide extract and monomeric compounds, namely gamabufalin, arenobufagin, telocinobufagin, bufotaline, cinobufagin, desacetylcinobufotalin, heloniogenin, resibufogenin, and cinobufotalin, and experimental results show that the bufadienolide compound has strong inhibition effect on tongue squamous cancer cells and compared with the bufadienolide extract and eight monomeric compounds, namely gamabufalin, arenobufagin, telocinobufagin, bufotaline, desacetylcinobufotalin, heloniogenin, resibufogenin, and cinobufotalin, cinobufagin has a stronger anti-tumor cell activity. The bufadienolide compound provided by the invention has clear components, controllable quality, strong anti-tumor activity and little adverse reaction and is expected to be developed into a novel anti oral mucosal malignant tumor medicine.

The invention belongs to the technical field of medical devices, and discloses a medical oncology drug delivery device and method, including a handle, a switch, a connecting rod, a transparent cover plate, a drug injection tube, a medicine mix cavity, a sleeve rod, a spring, a micro-photographic head, a medicine feeding pinhole, a micro motor, a chain, a barrier plate, a flat-head bent rod, a lighting lamp, a liquid level detection module, a wireless communication module, a smartphone, a housing and a tumor prediction module. A liquid level detection module detect that data information of theliquid level in the drug mixing cavity in time, and supply the drug liquid to the drug mixing cavity in time. The algorithm of wireless communication module can obtain better capacity performance, andthe difference between the algorithm and the optimal antenna selection algorithm is not very big, which not only maintains the diversity effect of wireless communication system, but also reduces thecomplexity of system coding. In addition, through the tumor prediction module to establish a tumor prediction model, can be more accurate in tumor prediction, to meet the needs of users.

The invention belongs to the field of antitumor drugs and specifically discloses application of aspirin in preparing medicine for treating NSCLC (non-small cell lung cancer). In comparison with the fact that osimertinib is applied alone to treat EGFR(+) NSCLC, the drug combination of the aspirin and the osimertinib can effectively inhibit proliferation of the EGFR(+) NSCLC cells, so as to promoteapoptosis of the EGFR(+) NSCLC cells. The drug combination of the aspirin and the osimertinib enhances sensitivity of the NSCLC patient to EGFR-TKI, overcomes the defect of highly possible drug resistance to the osimertinib, increases the effective treatment time of the osimertinib and can further improve the prognosis of the EGFR(+) NSCLC patient.

The invention provides application of fulvestrant in preparing an antimicrotubular chemotherapeutic drug resistance reversal agent. The fulvestrant reverts antimicrotubular chemotherapeutic drug resistance of breast cancer cells without relying whether estrogen receptors are expressed or not and also without relying whether the function of restricting P-glycoprotein is achieved or not. The fulvestrant and the antitumor drugs which are used together can accelerate the antitumor drugs to induce apoptosis of drug-resistance cells of breast cancer with negative estrogen receptors. The fulvestrant has been approved to be used for clinics and has the advantages of less side effects, good tolerance of a patient, less cross drug resistance with other estrogen receptor regulators or chemotherapeutic drugs, and the like, has clinical operability while being collaboratively used with common chemotherapeutic drugs for clinically treating the breast cancer, such as taxol, adriamycin, vinorelbine, and the like and has favorable clinical application prospect as the antimicrotubular chemotherapeutic drug resistance reversal agent for treating the drug-resistance breast cancer.

The invention discloses a screening model of drugs against head and neck cancer tumors. The screening model is constructed through the specific steps that (1) the surface of a hollow fiber reactor istransformed through acetic acid plasma, and sterilization treatment is conducted; (2) head and neck cancer tumor single cells are separated; (3) the head and neck cancer tumor single cells are plantedinto the hollow fiber reactor for cell adhesion culture; (4) a target drug is determined, a healthy mouse serves as a drug delivery target, the hollow fiber reactor is taken and planted into the backof the mouse, and a mouse head and neck cancer tumor pathological model is established after 24 h; and (5) the target drug is applied to the mouse head and neck cancer tumor pathological model, the drug is delivered once every two days, and the screening model of the drugs against the head and neck cancer tumors is constructed. According to the screening model, efficacy evaluation of the drugs against the head and neck cancer tumors can be quickly conducted, the time required by a pharmacological experiment of a traditional mouse xenograft model is greatly shortened, the time required from the experiment to the result does not exceed 20 days, the clinical experiment cost can be lowered, and the screening model is easy to popularize.

The invention discloses a polypeptide, an anti-tumor drug made from the polypeptide and a preparation method of the anti-tumor drug. The structural formula of the polypeptide is Ac-IIIIIIKKKKK-NH2. The anti-tumor drug includes a polypeptide nano drug carrier which is a nanosphere structure that can be broken in an acid environment, and a liposoluble drug is embedded into the polypeptide nano drug carrier. The preparation method of the anti-tumor drug includes the following steps that S1, the liposoluble drug and the polypeptide are dissolved in a DMSO; S2, a PBS buffer solution is added into the DMSO for ultrasonic mixing; S3, mixed liquid is added into dialysis bags for dialysis for 24 hours to remove the DMSO and unbound liposoluble drugs, and the prepared anti-tumor drug is obtained.

The invention provides an oncology drug processing device, which relates to the field of oncology. The oncology drug treatment device includes a motor and two brackets, a treatment box is arranged above the two brackets, the motor is fixedly connected to the right side of the treatment box, the treatment box is fixedly connected to the two brackets, and the inside of the treatment box is provided with Two grinding wheels, the left and right sides of the two grinding wheels are fixedly connected with four grinding plates, the four grinding plates located on the right side of the right grinding wheel are all clamped with fine grinding plates on the outside, and the inside of the processing box is inserted A rotating shaft is connected, the grinding wheel on the right is fixedly sleeved on the outside of the rotating shaft, the grinding wheel on the left is movably sleeved on the outside of the rotating shaft, and a control panel is arranged on the left side of the processing box. The oncology drug processing device achieves the effect of fully processing drugs by setting a motor, a rotating shaft, two grinding wheels and a grinding box, and solves the problem that the processing device in the prior art is not sufficiently ground and the time required for sufficient grinding longer.

Dry powder formulations for inhalation and their use in the treatment diseases and conditions. The formulation contains a uniform blend of a first spray-dried powder and a second spray-dried powder. The first spray-dried powder contains spray-dried particles of a therapeutically active ingredient dispersed in a pharmaceutically acceptable hydrophobic excipient. The second spray-dried powder contains spray-dried particles formed from a pharmaceutically acceptable hydrophobic excipient but are substantially free of any therapeutically active ingredient. The active ingredient in the first spray-dried powder is loaded sufficiently high to compensate for the second spray-dried powder being substantially free of any active ingredient. A process for preparing such formulations is also described.

The invention discloses a screening system and method for medical oncology treatment drugs. The method comprises the steps: acquiring the basic information of a first user; extracting gender information and age information of the first user from the basic information of the first user; acquiring a first feature vector of the first user; acquiring a first special label of the first user; acquiring a first screening condition according to the first feature vector and the first special label; extracting illness state information of the first user from the basic information of the first user; acquiring a second screening condition of the first user according to the illness state information of the first user; and inputting the first screening condition and the second screening condition into a medical oncology drug screening model to obtain a first drug screening result. The invention solves the technical problems that: in the prior art, due to the fact that the drug resistance of patients is different, suitable and efficient drugs cannot be dispensed accurately according to the specific conditions of the patients.

The invention relates to the technical field of esophageal injection, and discloses a medical oncology drug delivery device and a use method thereof.The medical oncology drug delivery device comprises a deep treatment bin penetrating into the body and a control handle installed at the far end of the deep treatment bin and connected with the deep treatment bin through a pipeline; the side face of the deep treatment bin is rotationally connected with an adjusting pipe used for guiding the injection direction, and angle adjusting mechanisms used for being matched with the control handle to control rotation are installed on the two sides of the adjusting pipe. When the deep treatment bin is inserted into the oral cavity, the external control handle is matched with the adjusting wheel set to drive the angle of the adjusting pipe on the side face of the deep treatment bin to change, the whole adjusting process is simple and convenient, and the injection head is very convenient to control during inclined injection and flat injection; in addition, the influence of a convex structure on injection is avoided aiming at the injection of nipple type diseases, the multi-angle switching injection for injection treatment aiming at the center, the basal part and the edge part of a tumor is more suitable, and the operation intensity of a doctor is reduced.

The invention relates to an anti-tumor drug composition. The anti-tumor drug composition is prepared from a composition of vinorelbine and afatinib. The combination drugs are used in combination of the vinorelbine and the afatinib. Compared with a single drug, the composition has a remarkable synergistic curative effect on the treatment of a lung cancer, and an in-vitro cell experiment proves thatproliferation of NSCLC cells can be effectively inhibited through the drug combination, a scientific basis is provided for the research and development of novel oncology drugs, and meanwhile, new research ideas are provided for other drug combinations.